About Agrisoma BioSciences
Agrisoma Biosciences is an agricultural company that has commercialized carinata, a non-food oilseed crop designed for sustainable production of biofuels. Agrisoma sells carinata seed products under the Resonance brand name, and uses advanced crop improvement technologies to provide superior crop varieties to growers.
Missing: Agrisoma BioSciences's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Agrisoma BioSciences's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Agrisoma BioSciences
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Agrisoma BioSciences is included in 3 Expert Collections, including Agriculture Technology (Agtech).
Agriculture Technology (Agtech)
Companies that are using technology to make farms more efficient.
Includes companies working on technology to support renewable energy generation.
Game Changers 2018
Agrisoma BioSciences Patents
Agrisoma BioSciences has filed 1 patent.
Brassicaceae, Leaf vegetables, Brassica, Medicinal plants, Vegetable oils
Brassicaceae, Leaf vegetables, Brassica, Medicinal plants, Vegetable oils
Latest Agrisoma BioSciences News
Nov 26, 2019
NuSeed acquires Agrisoma carinata assets In Louisiana, longtime industry executive Glenn Johnston said that NuSeed has acquired the carinata assets of Canadian agricultural pioneer Agrisoma. Johnston was speaking at the IATA Sustainable Aviation Fuels Symposium in New Orleans and confirmed that five Agrisoma staff members have joined NuSeed, with the asset acquisition. Terms of the acquisition have not been disclosed. NuSeed is a subsidiary of the Australian agricultural giant NuFarm, and Johnston indicated that NuSeed will carry forward development and especially deployment of Agrisoma’s carinata seeds to growers in the Americas and internationally. NuSeed focuses on the development and deployment of speciality crops including non gm canola, sorghum, and carinata. “NuSeed has even more capabilities and team members to bring carinata to more growers and increase the acreage,” said Johnston. “It’s very good news for the technology and those who worked at and with Agrisoma to bring the technology forward.” The Agrisoma backstory We reported in March last year that Agrisoma completed a C$12 million investment round . In addition to new investor Desjardins Capital, the lead investor Cycle Capital Management and existing investors BDC Capital and Lune Rouge also participated in the round. Back in 2017, Agrisoma Biosciences closed its $15.4 MM Series B financing round , co-led by new investor Groupe Lune Rouge and current investors Cycle Capital Management, and BDC Venture Capital. And, the company raised $8 million in its Series A investment round in 2014. That round was led by Cycle Capital Management and included participation of BDC Venture Capital. In April 2015, we reported a group led by its management team made an equity investment in the company that gave it a 22 percent stake in the company. The group includes key members of Agrisoma’s senior management, board members and advisors. Carinata: making a move in South America In 2017 we reported that Agrisoma and biorefinery giant UPM signed a long-term supply agreement that will expand the world’s only oilseed crop, developed to produce renewable fuels in South America. Under the deal, the two companies will grow Carinata oilseed crops with third-party farmers in Uruguay and Brazil. Yep, it’s sustainable, and RSB-certified, and off to Europe too Last July, we reported that Agrisoma hired Germany lobbying firm Alber and Geiger to help it get carinata included in the Renewable Energy Directive’s list of approved feedstock , a move that would allow for production across the EU-28 (future EU-27 by the time it’s likely approved). Already they report that the proposal has made it through a first hearing in the European Parliament, promoted by Hungarian and Czech MEPs, with the European Commission and Council currently looking at it. Carinata in flight A second international commercial flight powered by biojet fuel made from Carinata seed oil, the nonstop San Francisco-to-Zurich flight on a Boeing 787 departed Sept. 14 at 2:10 p.m. from San Francisco International Airport and arrived Sept. 15, at 10:10 a.m., at Zurich Airport, making it the longest biojet flight, then, to date. The biojet fuel made from Agrisoma’s Carinata and refined by World Energy’s Paramount facility replaced 30 percent of the petroleum jet fuel needed for the United Airlines flight. While they could have gone higher, 30 percent just worked out to be the number with all the logistics, said Fabijanski. Agrisoma CEO Steve Fabijanski told The Digest in an exclusive interview that these flights are demonstrating that the carinata crop has “legs beyond the diesel market. We’ve done over 20 million liters of diesel fuel, and this shows we can graduate to the jet market as well.” The Multi-Slide Guides Agrisoma Biosciences, Inc. has the world’s largest collection of Carinata and an extensive modern crop improvement program that allows them to select high yielding varieties ideally suited for production across a broad range of geographies. Agrisoma has commercialized Carinata in North and South America, working with hundreds of farmers on over 50,000 acres of production. The production of Agrisoma’s Resonance Carinata is being expanded to multiple locations globally to provide a supply of sustainable, non-food oils for meeting the demand for sustainable biofuels. Resonance Carinata is certified sustainable by the Roundtable on Sustainable Biomaterials (RSB), the global standard and certification scheme for sustainable biofuels. It is one of only four crops in the world to achieve that status. Resonance Carinata meal has recently received regulatory approval as an animal feed, further underscoring the value of this crop to meet the increasing demand for renewable fuel and providing meal for the production of livestock. Additionally, Resonance Carinata is grown on semi-arid farmland, creating new economic and production opportunities for growers. What’s happening with Agrisoma? The Digest’s understanding is that Agrisoma will continue to be active with some contracts the company will continue to manage, after which the Agrisoma board will decide the future direction or any potential operations. The Bottom Line The potential for Resonance Carinata to expand to multiple locations globally to provide a supply of sustainable, non-food oils for meeting the demand for sustainable biofuels — that’s the promise of this move. And, some good news for farmers pursuing off-season cover crops that make money, and potentially for other fuels as well, and for farmers seeking new feed options. There are geographies and times of the year where carinata fits like a glove, and NuSeed is well positioned to build on Agrisoma’s success. Every small company looks for a great exit, and here’s one. Kudos Agrisoma, kudos NuSeed.
Agrisoma BioSciences Frequently Asked Questions (FAQ)
Where is Agrisoma BioSciences's headquarters?
Agrisoma BioSciences's headquarters is located at 200, Rue Montcalm, Gatineau.
What is Agrisoma BioSciences's latest funding round?
Agrisoma BioSciences's latest funding round is Series C.
How much did Agrisoma BioSciences raise?
Agrisoma BioSciences raised a total of $31.71M.
Who are the investors of Agrisoma BioSciences?
Investors of Agrisoma BioSciences include BDC Venture Capital, Cycle Capital, Lune Rouge, Desjardins Capital, Canada-Israel Industrial Research and Development Fund and 3 more.
Who are Agrisoma BioSciences's competitors?
Competitors of Agrisoma BioSciences include Dicerna Pharmaceuticals, Pfenex, Cathay Industrial Biotech, Cell Point, Blue Heron Biotech, Agrivida, VirxSys, ZymoGenetics, Targeted Genetics, Sangamo Therapeutics and 15 more.
Compare Agrisoma BioSciences to Competitors
A company specialising in plant-based biotechnology projects with commercial and consumer interest.Plantechno holds several patents on technology to express human therapeutic and nutraceutical proteins in plants, as well as expression of genes to reduce the allergenic potential of certain foods. Plantechno is also committed to the development of platform technologies which improve the efficiency and utility of plant transformation.
Ventria Biosciences is a biotechnology company engaged in the development of recombinant proteins using its ExpressTec technology, which achieves yields far greater than those of the next-best plant-based system.
Welgen, Inc. is a biotech company developing technologies and products for biomedical research. The company was founded in 2002 to develop vectors for gene delivery and silencing that facilitate research activities in both academia and industry. The company's products provide the medical research community and the pharmaceutical industry with rapid and cost-efficient approaches for gene function research and drug development.
Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.
OrphageniX is a drug development company aiming to develop therapeutics for genetic diseases using advancements in "Gene Editing" technologies. OrpageniX will focus on the low volume, high margin specialty pharmaceutical niche area of "Orphan Diseases" which are protected under the Orphan Drug Act (ODA). Per the company, the OrphageniX technology can be used for diagnostics and research tools. Gene Editing uses the cell's innate repair mechanisms to repair mutations that result in genetic diseases. According to OrphaageniX, it is similar to gene therapy but avoids the risks associated with a viral vector. It works like anti-sense and RNAi, but is more efficient and permanent within the repaired cell because it changes the gene itself and not the transient message. The company states that it has major collaborations with Yale Medical School, Albert Einstein Medical Center and the University of Washington.
Stine Seed is an independent seed company dedicated to serving farmer customers with support from its team of agronomists and district and regional managers.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.